Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 4, 2012, Pages 1120-1125

  Huang, Jiayi ^a   Robertson, John M ^a   Ye, Hong ^a   Margolis, Jeffrey ^a   Nadeau, Laura ^a   Yan, Di ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Chemoradiotherapy; Duodenum DVH; Gastrointestinal toxicity; Gemcitabine; Pancreatic cancer

Indexed keywords

COX REGRESSION; DOSE-VOLUME ANALYSIS; DOSE-VOLUME HISTOGRAMS; DUODENUM DVH; ERLOTINIB; GASTROINTESTINAL TOXICITIES; GEMCITABINE; KAPLAN-MEIER; MULTIVARIATE ANALYSIS; PANCREATIC ADENOCARCINOMA; PANCREATIC CANCERS; RECEIVER OPERATING CHARACTERISTIC CURVES; RISK FACTORS; UNIVARIATE ANALYSIS;

CHEMORADIOTHERAPY; PATIENT MONITORING; RADIOTHERAPY; REGRESSION ANALYSIS;

TOXICITY;

ERLOTINIB; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DOSIMETRY; DUODENUM; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY; LIVER; LOCALLY ADVANCED PANCREAS ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RETROSPECTIVE STUDY; RISK FACTOR; SPINAL CORD;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DUODENUM; FEMALE; GASTROINTESTINAL TRACT; HUMANS; MALE; MIDDLE AGED; ORGANS AT RISK; PANCREATIC NEOPLASMS; QUINAZOLINES; RADIATION INJURIES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84862650276     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.09.022     Document Type: Article

References (18)

1. Ioka T, Nakamura S, Nishiyama K. A randomized phase II study of gemcitabine 1000mg/msq and concurrent radiotherapy comparing gemcitabine alone for unresectable locally advanced pancreatic adenocarcinoma [abstract]. Int J Radiat Oncol Biol Phys 2010;78:S102.
2. Huang J, Robertson JM, Margolis J, et al. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer. Radiother Oncol 2011;99:114-119.
3. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19: 4202-4208.
4. Small W Jr, Berlin J, Freedman GM, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: A multicenter phase II trial. J Clin Oncol 2008;26:942-947.
5. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45: 323-329.
6. Vargas C, Martinez A, Kestin LL, et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:1297-1308.
7. Yom SS, Liao Z, Liu HH, et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2007;68:94-102.
8. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124-1129.
9. Murphy JD, Adusumilli S, Griffith KA, et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007;68:801-808.
10. National Comprehensive Cancer Network. National Comprehensive Cancer Network practice guidelines for pancreatic cancer. Oncology (Williston Park) 1997;11:41-55.
11. Robertson JM, Margolis J, Jury RP, et al. A phase I study of conformal radiation therapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreas cancer. Int J Radiat Oncol Biol Phys 2011 [Epub ahead of print].
12. Robertson JM, Wallace M, Langenstein L. A phase I trial of hypofractionated intensity modulated radiation therapy with full dose gemcitabine for locally unresectable pancreatic cancer [abstract]. Proc Radiological Society of North America (RSNA) 2004;SSQ18:06.
13. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
14. Morgan MA, Parsels LA, Kollar LE, et al. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res 2008;14:5142-5149.
15. Murphy JD, Christman-Skieller C, Kim J, et al. A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys 2010;78:1420-1426.
16. Kim H, Lim do H, Paik SW, et al. Predictive factors of gastroduodenal toxicity in cirrhotic patients after three-dimensional conformal radiotherapy for hepatocellular carcinoma. Radiother Oncol 2009;93: 302-306.
17. Yovino S, Poppe M, Jabbour S, et al. Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys 2011; 79:158-162.
18. Ben-Josef E, Griffith K, Francis IR, et al. Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer [abstract]. J Clin Oncol 2009;27(15S):4602.